eXmoor Pharma
eXmoor Pharma is an integrated UK-based cell and gene therapy CDMO offering CMC consulting, process development, analytical services, GMP manufacturing, and facility design. Founded in 2004, it serves 190+ biotech, academic, and pharma clients from its MHRA-licensed 65,000 sq ft Bristol facility with 80+ experts.
- Company typePrivate
- Founded2004
- HeadquartersBristol, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What eXmoor Pharma does
eXmoor Pharma is a UK-based integrated cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) headquartered in Bristol. Founded in 2004 and operating in the CGT sector since 2007, the company delivers five interconnected service pillars: CMC consulting, process development, analytical services, GMP manufacturing, and facility design. Its purpose-built Cell & Gene Therapy Centre comprises 65,000 sq ft with four independent Grade C GMP clean rooms, a dedicated fill-finish suite, and capacity for 2x200L bioreactor scale or five autologous cell therapy stations. The facility received MHRA MIA(IMP) licensing in August 2024, enabling full GMP-grade manufacture for clinical trials.
The company serves 190+ clients globally including biotech companies (Quell Therapeutics, Tenpoint, Tavira, Imophoron), academic institutions (King's College London, UCL), nonprofits (Cancer Research UK, Anthony Nolan), and NHS partners (Royal Free London). Its differentiated integrated model embeds 20+ years of consultancy expertise across the full CMC journey, from early-phase strategy through to commercial readiness. The company employs 80+ experts, with 70% repeat business rate, and is backed by Kineticos Ventures and MVM Partners following a $35M Series A in May 2023.
Revenue is generated primarily through professional services fees for consulting, process development, and analytical work, plus managed services revenue from GMP manufacturing. The company targets enterprise clients through a direct sales team led by a Chief Commercial Officer, supplemented by industry events (BIO, ISCT, ESGCT), academic clinics with partner universities, and strategic regional partnerships including a Bangkok-based Southeast Asia expansion with Siam Bioscience announced in 2025. Geographic reach extends across the UK, US, Europe, and Southeast Asia, with planned facility expansion of 12,000 sq ft and headcount growth to 200 by 2027.
eXmoor Pharma firmographics
Firmographics- Name
- eXmoor Pharma
- Legal name
- eXmoor pharma concepts ltd
- Website
- https://exmoorpharma.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- eXmoor Pharma is an integrated UK-based cell and gene therapy CDMO offering CMC consulting, process development, analytical services, GMP manufacturing, and facility design. Founded in 2004, it serves 190+ biotech, academic, and pharma clients from its MHRA-licensed 65,000 sq ft Bristol facility with 80+ experts.
- Ownership category
- akta.pro rank
eXmoor Pharma industry classification
Industry- Product category
- Cell and Gene Therapy CDMO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where eXmoor Pharma is headquartered
LocationHeadquarters
- HQ city
- Bristol
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
eXmoor Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Consulting Services: CMC consulting, regulatory strategy, cost of goods analysis, investor and technical due diligence, GMP compliance consulting, and interim leadership positions. Revenue generated through project-based consulting engagements.
- Process Development Services: Process development for cell therapy, viral vectors, and RNA technologies including optimization and scale-up services.
- Analytical Services: Quality control and analytical testing services to ensure product safety, efficacy, and regulatory compliance.
- GMP Manufacturing: Clinical and commercial manufacturing services including clinical manufacturing, commercial manufacturing, cell banking, and fill finish under MHRA-licensed facility.
- Facility Design & Process Engineering: Concept design and process engineering services for CGT facility planning.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for consulting and development services |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
eXmoor Pharma product offering
Product offeringCore offering
eXmoor Pharma is an integrated cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that combines 20+ years of CMC and regulatory consultancy with a purpose-built 65,000 sq ft MHRA-licensed GMP manufacturing facility in Bristol, UK. It delivers end-to-end services across consulting, process development, analytical services, GMP manufacturing (clinical and commercial), and facility design for viral vectors, autologous and allogeneic cell therapies, and RNA technologies. The integrated model enables clients to progress therapies from early-phase strategy through to commercial readiness under a single provider.
Product overview
eXmoor Pharma is an integrated cell and gene therapy CDMO offering five interconnected service pillars: Consulting Services (CMC strategy, GMP compliance, QP services, due diligence), Process Development (cell therapy, viral vector, RNA), Analytical Services, GMP Manufacturing (clinical and commercial), and Facility Design & Process Engineering. These services are delivered through the company's purpose-built Cell & Gene Therapy Centre in Bristol, UK—a 65,000 sq ft facility with 4 Grade C clean rooms, fill-finish capability, and 2x200L bioreactor scale. The integrated model enables seamless progression from early-phase strategy through to commercial readiness, with a 70% repeat business rate and 190+ clients served worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- Consulting Services Expert CMC, regulatory and strategic consultancy for cell and gene therapy developers, covering CMC Consulting & Strategy, Cost of Goods analysis, Investor & Technical Due Diligence, GMP Compliance Consulting & QP Services, and Interim Leadership Positions to de-risk development and ensure regulatory success.
- Process Development Optimisation and scale-up of CGT processes covering cell therapy, viral vector (AAV, lentivirus) and RNA technologies to enable seamless progression from preclinical development through to GMP manufacturing and commercialisation.
- Analytical Services Generation of high-quality analytical data to ensure product safety, efficacy and regulatory compliance across cell and gene therapy manufacturing, supporting QC release and stability testing.
- GMP Manufacturing Regulatory-compliant, flexible GMP manufacturing services delivered from the MHRA MIA(IMP)-licensed Cell & Gene Therapy Centre, including Clinical Manufacturing, Commercial Manufacturing, Cell Banking, Fill Finish, and GMP Quality & Regulatory services for viral vectors, autologous and allogeneic cell therapies.
- Facility Design & Process Engineering End-to-end facility planning services for cell and gene therapy manufacturers, from concept design through process engineering to operational execution; 45 facility designs completed to date for clients globally.
Quantifiable outcome
- 70% repeat business rate demonstrating high client satisfaction
- +4 more outcomes
Companies that use eXmoor Pharma
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles4 records
eXmoor Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
eXmoor Pharma partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, minor and major.
- University College London (UCL)coreStrategic collaboration between eXmoor Pharma and UCL's Translational Research Office (TRO) to accelerate development of cell and gene therapies from academic research into clinical application. The partnership provides UCL innovators earlier access to CMC expertise, process development, GMP manufacturing, and regulatory strategy support.
- Royal Free London NHS Foundation TrustcoreStrategic collaboration to develop a scalable pathway for cell and gene therapy manufacturing in the UK, integrating CVIC's early-phase clinical manufacturing expertise with eXmoor's later-phase clinical manufacturing capabilities. Focus on harmonizing technology transfer, quality systems, and regulatory expertise.
- Ori BiotechminorCo-hosted The CGT Success Blueprint event in Boston with Ori Biotech and Kincell Bio, bringing together CGT developers, CDMOs, and academic leaders to discuss manufacturing and strategy.
- Kincell BiominorCo-hosted The CGT Success Blueprint event in Boston with Ori Biotech and Kincell Bio, featuring expert insights and patient perspective on CGT manufacturing.
- Siam BiosciencemajorStrategic partnership to establish a center for cell and gene therapy development and manufacturing in Bangkok, Thailand. Provides comprehensive services including consultancy, process development, and GMP clinical and commercial manufacturing to support therapy developers in Thailand and Southeast Asia.
- Anthony Nolan Cell Therapy and Laboratory ServicesmajorCollaboration to support developers of both autologous and allogeneic cell therapies. Combines Anthony Nolan's donor registry and expertise in cell collection with eXmoor's integrated process development and manufacturing services, emphasizing ethical sourcing and complete traceability of donor materials.
- Signadori BiomajorPartnership to develop next-generation monocyte-based cell therapy for solid tumours, combining Signadori Bio's therapeutic approach with eXmoor's process development and manufacturing capabilities.
- KU LeuvenmajorStrategic partnership announced to accelerate cell and gene therapy innovation through new venture, combining KU Leuven's research capabilities with eXmoor's manufacturing expertise.
- Quell TherapeuticscoreMulti-year manufacturing partnership for multiple autologous engineered CAR-Treg cell therapies for Phase 1/2 clinical studies. Builds on long-term relationship to provide dedicated GMP capacity at eXmoor's Cell & Gene Therapy Centre. Quell is the first manufacturing client in the new facility.
- ImophoronmajorStrategic process development partnership for Imophoron's ADDomer vaccine platform targeting RSV. eXmoor developing scalable manufacturing platform with future GMP manufacturing route at new facility.
Scale indicators11 records
Recent moves9 records
Expansion highlights5 records
eXmoor Pharma competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Global leader in CDMO services with significant cell and gene therapy capabilities including viral vector and cell therapy manufacturing. Offers a broad biologics portfolio and competes for the same CGT clients as eXmoor, but at much larger scale and global footprint.
- Catalent: Major CDMO with established cell therapy, viral vector, and biologics manufacturing services across multiple global sites. Provides comparable end-to-end development and manufacturing capabilities to eXmoor's clients, though at substantially larger scale and broader modality coverage.
- Charles River Laboratories: Large contract research and manufacturing organization with significant cell and gene therapy CDMO capabilities following its acquisition of Cobra Biologics. Competes with eXmoor for viral vector and cell therapy manufacturing projects globally.
- Thermo Fisher Scientific (Patheon): Diversified life sciences giant offering comprehensive CDMO services through its Patheon pharma services division including viral vector and cell therapy capabilities. Competes with eXmoor across multiple service categories at enterprise scale; eXmoor's CCO previously held roles in Thermo Fisher's Patheon unit.
Direct peers
- Oxford Biomedica: UK-based specialist CDMO focused on lentiviral vector development and manufacturing for cell and gene therapies. Directly comparable to eXmoor's viral vector services, with eXmoor's CTO James Miskin previously serving as CTO at Oxford Biomedica.
- AGC Biologics: Mid-to-large global CDMO offering cell and gene therapy, viral vector, and biologics manufacturing services. Direct competitor for CGT manufacturing contracts; eXmoor's CCO Manuel Balbuena previously held senior commercial roles at AGC Biologics.
- Andelyn Biosciences: Specialist AAV and gene therapy CDMO operating a purpose-built GMP facility in Columbus, Ohio. Closely comparable to eXmoor's gene therapy vector manufacturing offering and competing for similar early-stage to clinical-stage gene therapy clients.
Emerging players
- Kincell Bio: Emerging cell therapy CDMO focused on autologous and allogeneic cell therapy manufacturing. Co-hosted CGT Success Blueprint event with eXmoor in Boston, indicating close community overlap; directly comparable in scale and target customer base.
Regional players
- Centre for Process Innovation (CPI): UK-based national innovation centre offering biologics and cell/gene therapy process development, scale-up, and GMP manufacturing services. Directly comparable to eXmoor's UK operations and consulting-plus-CDMO model; CEO Lucy Foley joined eXmoor from CPI.
Others
- Cell and Gene Therapy Catapult: UK-based innovation accelerator supporting cell and gene therapy development with process development and manufacturing facilities. Operates in adjacent rather than directly competitive space, but is closely connected to the same ecosystem of UK CGT developers that form eXmoor's customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
eXmoor Pharma social profiles
Digital presenceeXmoor Pharma compliance and trust
Trust signalCompliance1 record
eXmoor Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
eXmoor Pharma leadership team
Management profileNumber of profiles
Profiles9 records
eXmoor Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
eXmoor Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about eXmoor Pharma
What does eXmoor Pharma do?
eXmoor Pharma is an integrated cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that combines 20+ years of CMC and regulatory consultancy with a purpose-built 65,000 sq ft MHRA-licensed GMP manufacturing facility in Bristol, UK. It delivers end-to-end services across consulting, process development, analytical services, GMP manufacturing (clinical and commercial), and facility design for viral vectors, autologous and allogeneic cell therapies, and RNA technologies. The integrated model enables clients to progress therapies from early-phase strategy through to commercial readiness under a single provider.
Is eXmoor Pharma a public or private company?
eXmoor Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was eXmoor Pharma founded?
eXmoor Pharma was founded in 2004. It employs 51 to 100 people.
Where is eXmoor Pharma based?
eXmoor Pharma is headquartered in Bristol, United Kingdom, in the Europe region.
How does eXmoor Pharma make money?
Five revenue lines are on record. Consulting Services are the primary driver. The others are process Development Services, analytical Services, GMP Manufacturing and facility Design & Process Engineering.
Who are eXmoor Pharma's main competitors?
Broad incumbents on record are Lonza Group, Catalent, Charles River Laboratories and Thermo Fisher Scientific (Patheon). Direct peers are Oxford Biomedica, AGC Biologics and Andelyn Biosciences. Kincell Bio is listed as an emerging player. Centre for Process Innovation (CPI) is listed as a regional player. Cell and Gene Therapy Catapult is listed as an others.
Does eXmoor Pharma have an API?
No public API is recorded for eXmoor Pharma.
What industry is eXmoor Pharma in?
eXmoor Pharma's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 541714 and its SIC code is 8731.